Lack of utility of CD20 immunohistochemistry in staging bone marrow biopsies for diffuse large B-cell lymphoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 17, Issue 2, 2009, Pages 93-95

  Baiyee, Daniel ^a   Warnke, Roger ^a   Natkunam, Yasodha ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow; CD20; Diffuse large B cell lymphoma; Immunohistochemistry; Staging

Indexed keywords

CD20 ANTIGEN;

ARTICLE; B LYMPHOCYTE; BONE MARROW; BONE MARROW BIOPSY; CANCER STAGING; CELL INFILTRATION; CELL SIZE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STAINING;

ANTIGENS, CD20; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM STAGING;

EID: 67849111408     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318184cd3f     Document Type: Article

References (17)

1. Arber DA, George TI. Bone marrow biopsy involvement by non- Hodgkin's lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens. Am J Surg Pathol. 2005;29:1549-1557.
2. Conlan MG, Bast M, Armitage JO, et al. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol. 1990;8:1163-1172. (Pubitemid 20195626)
3. Morra E, Lazzarino M, Castello A, et al. Bone marrow and blood involvement by non-Hodgkin's lymphoma: a study of clinicopathologic correlations and prognostic significance in relationship to the Working Formulation. Eur J Haematol. 1989;42:445-453. (Pubitemid 19150280)
4. Hodges GF, Lenhardt TM, Cotelingam JD. Bone marrow involvement in large-cell lymphoma. Prognostic implications of discordant disease. Am J Clin Pathol. 1994;101:305-311. (Pubitemid 24089577)
5. Yan Y, Chan WC, Weisenburger DD, et al. Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma. J Clin Oncol. 1995;13:1336-1342.
6. Chung R, Lai R, Wei P, et al. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood. 2007;110:1278-1282. (Pubitemid 47281426)
7. Campbell J, Seymour JF, Matthews J, et al. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol. 2006;76: 473-480.
8. Kubic VL, Brunning RD. Immunohistochemical evaluation of neoplasms in bone marrow biopsies using monoclonal antibodies reactive in paraffin-embedded tissue. Mod Pathol. 1989;2:618-629.
9. Maes B, Achten R, Demunter A, et al. Evaluation of B cell lymphoid infiltrates in bone marrow biopsies by morphology, immunohistochemistry, and molecular analysis. J Clin Pathol. 2000; 53:835-840. (Pubitemid 30836763)
10. van der Valk P, Mullink H, Huijgens PC, et al. Immunohistochemistry in bone marrow diagnosis. Value of a panel of monoclonal antibodies on routinely processed bone marrow biopsies. Am J Surg Pathol. 1989;13:97-106. (Pubitemid 19051194)
11. Bartl R, Frisch B, Burkhardt R, et al. Lymphoproliferations in the bone marrow: identification and evolution, classification and staging. J Clin Pathol. 1984;37:233-254. (Pubitemid 14192871)
12. Schmid C, Isaacson PG. Bone marrow trephine biopsy in lymphoproliferative disease. J Clin Pathol. 1992;45:745-750.
13. Thiele J, Zirbes TK, Kvasnicka HM, et al. Focal lymphoid aggregates (nodules) in bone marrow biopsies: differentiation between benign hyperplasia and malignant lymphoma-a practical guideline. J Clin Pathol. 1999;52:294-300. (Pubitemid 29161494)
14. Kremer M, Quintanilla-Martinez L, Nahrig J, et al. Immunohistochemistry in bone marrow pathology: a useful adjunct for morphologic diagnosis. Virchows Arch. 2005;447:920-937. (Pubitemid 41719547)
15. West RB, Warnke RA, Natkunam Y. The usefulness of immunohistochemistry in the diagnosis of follicular lymphoma in bone marrow biopsy specimens. Am J Clin Pathol. 2002;117:636-643. (Pubitemid 34823695)
16. Foran JM, Norton AJ, Micallef IN, et al. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. Br J Haematol. 2001; 114:881-883.
17. Seliem RM, Freeman JK, Steingart RH, et al. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab. Appl Immunohistochem Mol Morphol. 2006;14:18-23.